Weight, glucose, and metabolic health
This is where the mechanism meets the measured result.
What the phase 2 obesity and diabetes trials actually showed
This is where the mechanism meets the measured result. Retatrutide's two flagship phase 2 trials, an obesity study in the New England Journal of Medicine and a type 2 diabetes study in The Lancet, report large, dose-dependent effects on weight and blood sugar, and they remain the most fully documented human data on the drug.
They are no longer the only registration-grade evidence: the phase 3 diabetes trial TRANSCEND-T2D-1 was published in The Lancet in 2026, the phase 3 obesity trials have reported sponsor toplines, and two of them, TRIUMPH-1 and TRIUMPH-2, were published in full in September 2026. This unit reads the phase 2 numbers carefully, then places them against what the phase 3 program has added and what it has not.
Key terms
The obesity trial, dose by dose
The headline phase 2 obesity result is not a single number but a staircase: each higher dose produced more weight loss, all the way to about 24% at 48 weeks on the top dose. A clear dose-response like this is one of the strongest hints that an effect is real and drug-driven, not chance.
The curve flattens a little at the top but is still climbing at the highest dose tested. The phase 3 program kept 12 mg as its top dose and ran it for longer instead: in TRIUMPH-1, 80 weeks on 12 mg produced a 25.0% average loss against 3.9% on placebo in the published paper, and 28.3% against 2.2% on the company's efficacy estimand. Remember the placebo group here lost only about 2%, so almost all of this staircase is genuine drug effect.
AdvancedWhy dose-response builds confidence
A clean dose-response, more drug giving more effect in an orderly way, is a classic signature of a real pharmacological effect. It is much harder to explain by bias or chance than a single positive number, which is why trialists prize it.